

**ondine**



**For Immediate Release**

**Ondine Announces Consolidation of US Operations  
into New Bothell, WA Facilities**

**Vancouver, Canada – April 18, 2007** - Ondine Biopharma Corporation (TSX: OBP; AIM: OBP) announced today a significant expansion of its US-based facilities, providing the basis for accelerated product development in both the oral care and MRSA sectors. Ondine's wholly owned research subsidiary will vacate its facilities in Redmond and move into new premises located in Bothell, Washington.

Ondine will also close its office in York, Pennsylvania, and sales and marketing functions will be consolidated to Ondine's corporate head office in Vancouver, B.C. and the new Bothell, Washington facility. York-based Jacqueline Walker, Chief Operating Officer, will be leaving the company. Tom Leonardi, also based in York, will be stepping down as Vice President of Sales and Marketing of Ondine Biopharma (U.S.A.) Inc., in order to pursue opportunities outside the company. The Company is grateful for the important contributions that Jacqueline and Tom have made to Ondine, and wishes them every success in the future.

"Consolidation of our operations enables greater efficiency and effectiveness, essential to meeting upcoming milestones," said Carolyn Cross, President and CEO of Ondine. "The move to our new facilities allows our product development teams to work closely together as we continue to evolve Periowave™, our groundbreaking Photodisinfection technology, and develop the next generation of MRSA anti-infectives, leveraging our recent Canadian and European approvals."

**About Periowave™ and Photodisinfection (PDD)**

Periowave™ is a Photodisinfection system developed by Ondine that utilizes low-intensity lasers and wavelength-specific, light-activated compounds to specifically target and destroy microbial pathogens and reduce the symptoms of disease. The compounds are generally topically applied and one or more lasers are used to activate the compounds and complete the disinfection. The Photodisinfection technologies were developed by Professor Michael Wilson and colleagues at the Eastman Dental Institute, University College London, and licensed to Ondine by UCL Business PLC, University College London. Additional information about Periowave™ is available at [www.periowave.com](http://www.periowave.com).

**About Ondine Biopharma Corporation:**

Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial, fungal and viral infections. The Company is focused on creating and commercializing leading-edge products utilizing its patented light-activated technology. Photodisinfection provides broad-spectrum antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance. The Company is headquartered in Vancouver, British Columbia, Canada, with a research laboratory in Bothell, Washington, USA and an international office in St Michael, Barbados. For additional information, please visit the Company's website at: [www.ondinebiopharma.com](http://www.ondinebiopharma.com).

*Forward-Looking Statements:*

*Certain statements contained in this release containing words like "believe", "intend", "may", "expect" and other similar expressions, are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the Company's forward-looking statements include the following: market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain and develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products and other risk factors identified from time to time in the Company's filings.*

**For further information please contact:**

Carolyn Cross  
President and Chief Executive Officer  
Ondine Biopharma Corporation  
(604) 669-0555  
[ccross@ondinebiopharma.com](mailto:ccross@ondinebiopharma.com)

Christina Bessant  
Investor Relations  
The Equicom Group Inc.  
(416) 815-0700 ext. 269  
[cbessant@equicomgroup.com](mailto:cbessant@equicomgroup.com)